The stock has a 36-month beta value of 1.54. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DMAC is 24.02M, and at present, short sellers hold a 0.80% of that float. On February 20, 2025, the average trading volume of DMAC was 108.16K shares.
DMAC) stock’s latest price update
The stock price of DiaMedica Therapeutics Inc (NASDAQ: DMAC) has jumped by 7.95 compared to previous close of 6.16. Despite this, the company has seen a gain of 5.89% in its stock price over the last five trading days. businesswire.com reported 2025-02-10 that MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025 at 11:20am Eastern Time. Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Oppenheimer representative to a.
DMAC’s Market Performance
DiaMedica Therapeutics Inc (DMAC) has experienced a 5.89% rise in stock performance for the past week, with a 16.46% rise in the past month, and a 61.41% rise in the past quarter. The volatility ratio for the week is 6.36%, and the volatility levels for the past 30 days are at 6.00% for DMAC. The simple moving average for the past 20 days is 8.36% for DMAC’s stock, with a 58.44% simple moving average for the past 200 days.
Analysts’ Opinion of DMAC
Many brokerage firms have already submitted their reports for DMAC stocks, with H.C. Wainwright repeating the rating for DMAC by listing it as a “Buy.” The predicted price for DMAC in the upcoming period, according to H.C. Wainwright is $7 based on the research report published on October 07, 2024 of the previous year 2024.
Craig Hallum, on the other hand, stated in their research note that they expect to see DMAC reach a price target of $8. The rating they have provided for DMAC stocks is “Buy” according to the report published on April 24th, 2024.
Oppenheimer gave a rating of “Outperform” to DMAC, setting the target price at $7 in the report published on June 22nd of the previous year.
DMAC Trading at 16.78% from the 50-Day Moving Average
After a stumble in the market that brought DMAC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 3.10% of gains for the given period.
Volatility was left at 6.00%, however, over the last 30 days, the volatility rate increased by 6.36%, as shares surge +14.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.02% upper at present.
During the last 5 trading sessions, DMAC rose by +5.89%, which changed the moving average for the period of 200-days by +156.76% in comparison to the 20-day moving average, which settled at $6.14. In addition, DiaMedica Therapeutics Inc saw 22.47% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DMAC starting from Von Koch Thomas, who purchase 1,200,000 shares at the price of $2.50 back on Jun 28 ’24. After this action, Von Koch Thomas now owns 5,526,435 shares of DiaMedica Therapeutics Inc, valued at $3,000,000 using the latest closing price.
STAHLBERG JAN, the 10% Owner of DiaMedica Therapeutics Inc, purchase 1,200,000 shares at $2.50 during a trade that took place back on Jun 28 ’24, which means that STAHLBERG JAN is holding 5,221,608 shares at $3,000,000 based on the most recent closing price.
Stock Fundamentals for DMAC
Current profitability levels for the company are sitting at:
- -0.76 for the present operating margin
- 0.78 for the gross margin
The net margin for DiaMedica Therapeutics Inc stands at -0.7. The total capital return value is set at -0.49. Equity return is now at value -41.90, with -39.23 for asset returns.
Based on DiaMedica Therapeutics Inc (DMAC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -52.66. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -4.08.
Currently, EBITDA for the company is -19.31 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 9.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.81.
Conclusion
To sum up, DiaMedica Therapeutics Inc (DMAC) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
